• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Autolus Therapeutics plc

    11/14/24 1:44:27 PM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AUTL alert in real time by email
    SC 13G/A 1 d901415dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 7)*

     

     

    Autolus Therapeutics plc

    (Name of Issuer)

    American Depositary Shares and Ordinary Shares, nominal value $0.000042 per share

    (Title of Class of Securities)

    05280R 100**

    (CUSIP Number)

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    **

    There is no CUSIP number assigned to the ordinary shares. CUSIP number 05280R 100 has been assigned to the American Depositary Shares of the Issuer, which are quoted on the Nasdaq Global Select Market under the symbol “AUTL.” Each American Depositary Share represents the right to receive one ordinary share.

     

     

     


    SCHEDULE 13G/A

    CUSIP No. 05280R 100

     

     1   

     Names of Reporting Person:

     

     Syncona Portfolio Limited

     2  

     Check the appropriate box if a member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Guernsey

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     30,734,957 (1)

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     30,734,957 (1)

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     30,734,957 (1)

    10  

     Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    11  

     Percent of class represented by amount in row (9)

     

     11.6% (2)

    12  

     Type of Reporting Person (See Instructions)

     

     CO

     

    (1)

    Consists of 12,180,333 ordinary shares and 18,554,624 American Depositary Shares (“ADSs”) held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value $0.000042 per share, of the Issuer. The ordinary shares and the ADSs are collectively referred to as the “Ordinary Shares”.

    (2)

    Based on 266,094,457 Ordinary Shares outstanding as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 6, 2024.

     

    Page 2 of 11


    SCHEDULE 13G/A

    CUSIP No. 05280R 100

     

     1   

     Names of Reporting Person:

     

     Syncona Holdings Limited

     2  

     Check the appropriate box if a member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Guernsey

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     30,734,957 (1)

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     30,734,957 (1)

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     30,734,957 (1)

    10  

     Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    11  

     Percent of class represented by amount in row (9)

     

     11.6% (2)

    12  

     Type of Reporting Person (See Instructions)

     

     CO

     

    (1)

    Consists of 12,180,333 ordinary shares and 18,554,624 ADSs held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value $0.000042 per share, of the Issuer.

    (2)

    The percentage of outstanding Ordinary Shares of the Issuer beneficially owned by Syncona Portfolio Limited is set forth on Line 11 above. Based on 266,094,457 Ordinary Shares outstanding as reported in the Issuer’s Form 10-Q filed with the SEC on August 6, 2024.

     

    Page 3 of 11


    SCHEDULE 13G/A

    CUSIP No. 05280R 100

     

     1   

     Names of Reporting Person:

     

     Syncona Investment Management Limited

     2  

     Check the appropriate box if a member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     United Kingdom

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     30,734,957 (1)

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     30,734,957 (1)

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     30,734,957 (1)

    10  

     Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    11  

     Percent of class represented by amount in row (9)

     

     11.6% (2)

    12  

     Type of Reporting Person (See Instructions)

     

     CO

     

    (1)

    Consists of 12,180,333 ordinary shares and 18,554,624 ADSs held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value $0.000042 per share, of the Issuer.

    (2)

    The percentage of outstanding Ordinary Shares of the Issuer beneficially owned by Syncona Portfolio Limited is set forth on Line 11 above. Based on 266,094,457 Ordinary Shares outstanding as reported in the Issuer’s Form 10-Q filed with the SEC on August 6, 2024.

     

    Page 4 of 11


    SCHEDULE 13G/A

    CUSIP No. 05280R 100

     

     1   

     Names of Reporting Person:

     

     Syncona Limited

     2  

     Check the appropriate box if a member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Guernsey

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     30,734,957 (1)

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     30,734,957 (1)

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     30,734,957 (1)

    10  

     Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    11  

     Percent of class represented by amount in row (9)

     

     11.6% (2)

    12  

     Type of Reporting Person (See Instructions)

     

     CO

     

    (1)

    Consists of 12,180,333 ordinary shares and 18,554,624 ADSs held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value $0.000042 per share, of the Issuer.

    (2)

    The percentage of outstanding Ordinary Shares of the Issuer beneficially owned by Syncona Portfolio Limited is set forth on Line 11 above. Based on 266,094,457 Ordinary Shares outstanding as reported in the Issuer’s Form 10-Q filed with the SEC on August 6, 2024.

     

    Page 5 of 11


    SCHEDULE 13G/A

    CUSIP No. 05280R 100

     

     1   

     Names of Reporting Person:

     

     Roel Bulthuis

     2  

     Check the appropriate box if a member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Netherlands

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     30,734,957 (1)

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     30,734,957 (1)

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     30,734,957 (1)

    10  

     Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    11  

     Percent of class represented by amount in row (9)

     

     11.6% (2)

    12  

     Type of Reporting Person (See Instructions)

     

     IN

     

    (1)

    Consists of 12,180,333 ordinary shares and 18,554,624 ADSs held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value $0.000042 per share, of the Issuer.

    (2)

    The percentage of outstanding Ordinary Shares of the Issuer beneficially owned by Syncona Portfolio Limited is set forth on Line 11 above. Based on 266,094,457 Ordinary Shares outstanding as reported in the Issuer’s Form 10-Q filed with the SEC on August 6, 2024.

     

    Page 6 of 11


    CUSIP No. 05280R 100

     

     1   

     Names of Reporting Person:

     

     Christopher Hollowood

     2  

     Check the appropriate box if a member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     United Kingdom

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     30,734,957 (1)

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     30,734,957 (1)

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     30,734,957 (1)

    10  

     Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    11  

     Percent of class represented by amount in row (9)

     

     11.6% (2)

    12  

     Type of Reporting Person (See Instructions)

     

     IN

     

    (1)

    Consists of 12,180,333 ordinary shares and 18,554,624 ADSs held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value $0.000042 per share, of the Issuer.

    (2)

    The percentage of outstanding Ordinary Shares of the Issuer beneficially owned by Syncona Portfolio Limited is set forth on Line 11 above. Based on 266,094,457 Ordinary Shares outstanding as reported in the Issuer’s Form 10-Q filed with the SEC on August 6, 2024.

     

    Page 7 of 11


    Item 1.

    (a) Name of Issuer: Autolus Therapeutics plc

    (b) Address of Issuer’s principal executive offices: The Mediaworks, 191 Wood Lane, London W12 7FP, United Kingdom

     

    Item 2.

     

    (a)

    Name of reporting persons filing:

     

      (i)

    Syncona Portfolio Limited;

     

      (ii)

    Syncona Holdings Limited;

     

      (iii)

    Syncona Investment Management Limited;

     

      (iv)

    Syncona Limited;

     

      (v)

    Roel Bulthuis; and

     

      (vi)

    Christopher Hollowood

     

    (b)

    Address of principal business office or, if none, residence:

    The address of the principal business office of Syncona Portfolio Limited, Syncona Holdings Limited and Syncona Limited is Frances House, PO Box 273, Sir William Place, St. Peter Port, Guernsey, GY1 3RD, Channel Islands. The address of the principal business office of Syncona Investment Management Limited, Roel Bulthuis and Christopher Hollowood is 2nd Floor, 8 Bloomsbury Street, London WC1B 3SR, United Kingdom.

     

    (c)

    Citizenship:

    Syncona Portfolio Limited, Syncona Holdings Limited and Syncona Limited’s citizenship is Guernsey. Syncona Investment Management Limited and Christopher Hollowood’s citizenship is United Kingdom. Roel Bulthuis’ citizenship is the Netherlands.

     

    (d)

    Title and class of securities:

    Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares (“ADS”). Each ADS represents one ordinary share, nominal value $0.000042 per share, of the Issuer.

     

    (e)

    CUSIP No.:

    There is no CUSIP number assigned to the ordinary shares. CUSIP number 05280R 100 has been assigned to the ADS, which are quoted on the Nasdaq Global Select Market under the symbol “AUTL.”

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership:

    The following information with respect to the ownership of Ordinary Shares of the Issuer by the Reporting Persons filing this statement on Schedule 13G/A is provided as of December 31, 2023:

     

    Page 8 of 11


    Reporting Persons

       Ordinary
    Shares Held
    Directly (1)
         Sole
    Power
    to Vote
    or
    Direct
    the
    Vote (1)
         Shared
    Power to
    Vote or
    Direct the
    Vote (1)
         Sole
    Power to
    Dispose or
    Direct the
    Disposition
    (1)
         Shared
    Power to
    Dispose or
    Direct the
    Disposition
    (1)
         Amount
    Beneficially
    Owned (1)
         Percentage
    of Class (2)
     

    Syncona Portfolio Limited

         30,734,957        0        30,734,957        0        30,734,957        30,734,957        11.6 % 

    Syncona Holdings Limited

         0        0        30,734,957        0        30,734,957        30,734,957        11.6 % 

    Syncona Investment Management Limited

         0        0        30,734,957        0        30,734,957        30,734,957        11.6 % 

    Syncona Limited

         0        0        30,734,957        0        30,734,957        30,734,957        11.6 % 

    Roel Bulthuis

         0        0        30,734,957        0        30,734,957        30,734,957        11.6 % 

    Christopher Hollowood

         0        0        30,734,957        0        30,734,957        30,734,957        11.6 % 

     

    (1)

    Consists of 12,180,333 ordinary shares and 18,554,624 ADSs held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value $0.000042 per share, of the Issuer.

    (2)

    The percentage of outstanding Ordinary Shares of the Issuer beneficially owned was calculated based on 266,094,457 Ordinary Shares outstanding as reported in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

    The shares are owned directly by Syncona Portfolio Limited (“Syncona Portfolio”) and indirectly by Syncona Holdings Limited (“Syncona Holdings”), Syncona Limited (“Syncona Limited”), Roel Bulthuis and Christopher Hollowood. Syncona Portfolio is a wholly owned subsidiary of Syncona Holdings, and Syncona Holdings is a wholly controlled subsidiary of Syncona Limited, a publicly-listed company. Investment and voting decisions with respect to these shares are made by Syncona Portfolio, acting upon the recommendation of Roel Bulthuis and Christopher Hollowood, who comprise the investment committee of Syncona Investment Management Limited, also a subsidiary of Syncona Holdings. On November 16, 2023, Roel Bulthuis replaced Martin Murphy on the investment committee of Syncona Investment Management Limited. Each of these entities disclaims beneficial ownership except to the extent of its pecuniary interest therein, if any.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of more than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

    Not applicable.

     

    Item 8.

    Identification and classification of members of the group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certifications.

    Not applicable.

     

    Page 9 of 11


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 14, 2024

     

    SYNCONA PORTFOLIO LIMITED
    By:  

    /s/ Nicholas Moss

    Name:   Nicholas Moss
    Title:   Director
    SYNCONA HOLDINGS LIMITED
    By:  

    /s/ Nicholas Moss

    Name:   Nicholas Moss
    Title:   Director
    SYNCONA INVESTMENT MANAGEMENT LIMITED
    By:  

    /s/ Christopher Hollowood

    Name:   Christopher Hollowood
    Title:   CEO
    SYNCONA LIMITED
    By:  

    /s/ Robert Hutchinson

    Name:   Robert Hutchinson
    Title:   Director

     

         

    /s/ Roel Bulthuis

      Roel Bulthuis
     

    /s/ Christopher Hollowood

      Christopher Hollowood

     

    Exhibit(s):     
    Exhibit 99.1:    Joint Filing Statement
    Get the next $AUTL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AUTL

    DatePrice TargetRatingAnalyst
    11/18/2024$7.00 → $7.60Neutral → Buy
    Goldman
    11/15/2024$13.00Neutral → Buy
    Redburn Atlantic
    11/9/2023$10.00Buy
    Deutsche Bank
    3/27/2023$8.00Overweight
    Wells Fargo
    3/17/2023$5.00Buy
    Bryan Garnier
    More analyst ratings

    $AUTL
    SEC Filings

    See more
    • SEC Form EFFECT filed by Autolus Therapeutics plc

      EFFECT - Autolus Therapeutics plc (0001730463) (Filer)

      5/16/25 12:15:27 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by Autolus Therapeutics plc

      424B3 - Autolus Therapeutics plc (0001730463) (Filer)

      5/15/25 4:13:24 PM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Autolus Therapeutics plc

      SCHEDULE 13G/A - Autolus Therapeutics plc (0001730463) (Subject)

      5/12/25 10:24:40 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AUTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Autolus Therapeutics upgraded by Goldman with a new price target

      Goldman upgraded Autolus Therapeutics from Neutral to Buy and set a new price target of $7.60 from $7.00 previously

      11/18/24 7:38:09 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Autolus Therapeutics upgraded by Redburn Atlantic with a new price target

      Redburn Atlantic upgraded Autolus Therapeutics from Neutral to Buy and set a new price target of $13.00

      11/15/24 7:30:20 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Deutsche Bank initiated coverage on Autolus Therapeutics with a new price target

      Deutsche Bank initiated coverage of Autolus Therapeutics with a rating of Buy and set a new price target of $10.00

      11/9/23 6:38:44 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AUTL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

      LONDON, May 14, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of three abstracts submitted to the European Hematology Association (EHA) Congress, to be held June 12-15, 2025, Milan, Italy. Autolus will have two oral and one poster presentation, which includes updated follow up from the FELIX study of obecabtagene autoleucel (obe-cel) in adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). Oral S113: Title: Can CAR T-cell therapy be a definitive treatment for ad

      5/14/25 9:30:00 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

      Company reports Q1 2025 AUCATZYL® net product revenue of $9.0 millionU.K. Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for AUCATZYL® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL)Encouraging preliminary data reported in Phase 1 CARLYSLE trial in systemic lupus erythematosus (SLE); planned Phase 2 pivotal clinical trial in lupus nephritis (LN) and Phase 1 clinical trial in progressive forms of multiple sclerosis (MS) initiating before year-end 2025Conference call to be held today at 08:30 am EDT/13:30 pm GMT: conference call participants should pre-register usin

      5/8/25 7:00:00 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

      UK Medicines and Healthcare products Regulatory Agency (MHRA) authorisation based on FELIX clinical trial of obecabtagene autoleucel in adult patients with r/r B-ALL1AUCATZYL® licensed from MHRA under ‘conditional marketing authorisation', meaning that the MHRA will review new efficacy and safety information at least once every year1 Investors, US and UK National, Medical and Industry media only LONDON, April 25, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces today that the UK Medicines and Healthcare products

      4/25/25 12:06:39 PM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AUTL
    Financials

    Live finance-specific insights

    See more

    $AUTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

      Company reports Q1 2025 AUCATZYL® net product revenue of $9.0 millionU.K. Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for AUCATZYL® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL)Encouraging preliminary data reported in Phase 1 CARLYSLE trial in systemic lupus erythematosus (SLE); planned Phase 2 pivotal clinical trial in lupus nephritis (LN) and Phase 1 clinical trial in progressive forms of multiple sclerosis (MS) initiating before year-end 2025Conference call to be held today at 08:30 am EDT/13:30 pm GMT: conference call participants should pre-register usin

      5/8/25 7:00:00 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

      Company outlined potential for value creation driven by obe-cel across multiple B cell driven malignancies and autoimmune diseases, including acute lymphoblastic leukemia (ALL), lupus nephritis (LN) and multiple sclerosis (MS)Preliminary data in initial six patient cohort treated in Phase 1 trial in systemic lupus erythematosus (SLE) support progressing obe-cel into a planned Phase 2 pivotal study in lupus nephritis; first patient expected to be dosed in Phase 2 trial by year-end 2025Company plans to advance obe-cel in progressive forms of multiple sclerosis (MS); first patient expected to be dosed in Phase 1 trial by year-end 2025 LONDON, April 23, 2025 (GLOBE NEWSWIRE) -- Autolus Therap

      4/23/25 4:05:00 PM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

      LONDON, April 22, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its first quarter 2025 financial results and operational highlights before open of US markets on Thursday, May 8, 2025. Management will host a conference call and webcast at 8:30 am EDT/13:30 pm BST to discuss the company's financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conferenc

      4/22/25 7:00:00 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Autolus Therapeutics plc

      SC 13G/A - Autolus Therapeutics plc (0001730463) (Subject)

      11/14/24 4:32:31 PM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Autolus Therapeutics plc

      SC 13G/A - Autolus Therapeutics plc (0001730463) (Subject)

      11/14/24 1:44:27 PM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Autolus Therapeutics plc

      SC 13G/A - Autolus Therapeutics plc (0001730463) (Subject)

      11/14/24 9:12:16 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AUTL
    Leadership Updates

    Live Leadership Updates

    See more
    • Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

      Innate to propose to its Annual General Meeting taking place on May 22, 2025, to move from an executive board/supervisory board corporate governance structure to a CEO/board of directors Irina Staatz-Granzer, current Chairwoman of the Supervisory board would be appointed Chairwoman of the board of Directors Jonathan Dickinson, current Chairman of the Executive board would be appointed Chief Executive Officer and named to the board of Directors Two new members would join the board of Directors Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced it will propose to its Annual General Meeting taking place on May 22, 2025, to move from

      4/16/25 1:00:00 AM ET
      $AUTL
      $IPHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer

      LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced the appointment of Matthias Will, M.D., as Chief Development Officer. Dr. Will is joining Autolus' executive team and will lead the company's development organization effective September 30, 2024. "Matthias has a proven track record of success in pharmaceutical product development, achieving many key regulatory milestones and marketing approvals across several cancer indications," said Dr. Christian Itin, Chief Executive Officer of Autolus. "His in-depth development experience and leadership skil

      9/19/24 7:00:00 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Autolus Therapeutics Announces Changes to its Board of Directors

      LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the appointment of Mike Bonney as Chairman of the Board, and Ravi Rao M.D., as Non-Executive Director. John H. Johnson advised the Board of his decision to step down from his role as Chairman of the Board and Non-Executive Director. These changes are effective as of today, April 1, 2024. "On behalf of the Board and Management team, we would like to thank John for his leadership during a transformational period for the Company, which included conducting the pivotal Phase 2 FELIX study and th

      4/1/24 7:00:00 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care